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Glucose constitutes a major fuel for the heart, and
high glucose uptake during fetal development is coinci-
dent with the highest level of expression of the glucose
transporter GLUT-1 during life. We have previously re-
ported that GLUT-1 is repressed perinatally in rat heart,
and GLUT-4, which shows a low level of expression in
the fetal stage, becomes the main glucose transporter in
the adult. Here, we show that the perinatal expression of
GLUT-1 and GLUT-4 glucose transporters in heart is
controlled directly at the level of gene transcription.
Transient transfection assays show that the 299/233
fragment of the GLUT-1 gene is sufficient to drive tran-
scriptional activity in rat neonatal cardiomyocytes.
Electrophoretic mobility shift assays demonstrate that
the transcription factor Sp1, a trans-activator of GLUT-1
promoter, binds to the 2102/282 region of GLUT-1 pro-
moter during the fetal state but not during adulthood.
Mutation of the Sp1 site in this region demonstrates that
Sp1 is essential for maintaining a high transcriptional
activity in cardiac myocytes. Sp1 is markedly down-reg-
ulated both in heart and in skeletal muscle during neo-
natal life, suggesting an active role for Sp1 in the regu-
lation of GLUT-1 transcription. In all, these results
indicate that the expression of GLUT-1 and GLUT-4 in
heart during perinatal development is largely con-
trolled at a transcriptional level by mechanisms that
might be related to hyperplasia and that are independ-
ent from the signals that trigger cell hypertrophy in the
developing heart. Furthermore, our results provide the
first functional insight into the mechanisms regulating
muscle GLUT-1 gene expression in a live animal.
Facilitative glucose uptake in mammalian cells is mediated
by a family of glucose transporter proteins (GLUT-1 to
GLUT-5) (1). The pattern of expression of these proteins is very
complex: GLUT-1 is found in virtually all tissues and seems to
be responsible for the basal glucose uptake (2), whereas
GLUT-4 is mainly expressed in the peripheral insulin-sensitive
tissues (skeletal and cardiac muscle and brown and white
adipose tissue) (1). In insulin-sensitive-tissues, insulin is able
to induce a rapid increase in glucose uptake, and this effect is
due to the recruitment of GLUT-4 glucose transporters from an
intracellular pool to the plasma membrane (3). Insulin-sensi-
tive tissues express both GLUT-4 and GLUT-1, although
GLUT-4 is the major glucose transporter isoform. Thus, in the
rat adipose tissue, 90% of glucose transporters expressed are
GLUT-4 (4), and a similar percentage has been observed in
skeletal muscle (5). A higher relative expression of GLUT-1 has
been observed in rat cardiomyocytes, where GLUT-1 expres-
sion accounts for 30% of the total glucose transporters (6).
There are several reports (7, 8) indicating that in the fetal
heart, and also in other muscles, glucose consumption is very
high during the late fetal stage and that the response to insulin
increases postnatally (7). Moreover, the glycogen content in
fetal heart and other tissues is higher in near-term fetuses
than in the mature rat (9). This may constitute an adaptive
trait that would confer protection against hypoxic stress in the
fetus during delivery (10). Given that glucose transport is a
rate-limiting step for glycolysis (11), it is feasible that main-
taining a high level of expression of GLUT-1 would be crucial
for the fetus, because a constitutive high glucose transport rate
would be ensured this way and would help to overcome any
hypoxic events that may arise during birth. Thus, anaerobic
metabolism of glucose would fulfill the ATP demand of the
fetus during the hypoxic episode. Furthermore, the relevance of
maintaining appropriate expression levels of GLUT-1 in vivo
has been recently highlighted by Seidner et al. (12); they at-
tribute the cause of a severe human brain disorder to the
existence of mutations in GLUT-1 gene that reduce the expres-
sion of this transporter, which is specially detrimental to the
energy metabolism of brain. It has also been pointed out that
an increase in glucose availability may be beneficial for reduc-
ing the stress during cardiac ischemic episodes (13–15).
The expression of GLUT-1 and GLUT-4 glucose transporters
is strongly regulated during the perinatal development of rat
heart, skeletal muscle, and brown adipose tissue. We have
described (16) that around birth and during the first weeks of
neonatal life, glucose transporter expression is characterized
by a dramatic change in the accumulations of GLUT-1 and
GLUT-4, both mRNA and protein, in rat heart, in skeletal
muscle, and in brown adipose tissue. Regarding the signals
regulating these processes, we have previously shown (17) that
thyroid hormones have an essential role in the maintenance of
the postnatal induction of GLUT-4 and the repression of
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GLUT-1 in rat heart. Whether this effect is direct or not is still
unknown. In further studies performed in the L6E9 skeletal
muscle cell line, we have observed that the differentiation of
myoblasts into myotubes is associated with the repression of
the expression of GLUT-1 and the induction of GLUT-4 (18). In
these cells, the 299/233 region of the GLUT-1 proximal pro-
moter drives transcriptional activity of GLUT-1 and partici-
pates in the reduced transcription after muscle differentiation.
Furthermore, we have shown that the Sp1 zinc-finger tran-
scription factor is able to bind to a putative binding site in
291/286 of the GLUT-1 promoter. Sp1 is able to trans-activate
the GLUT-1 promoter in L6E9 cells, and its own expression
undergoes down-regulation during muscle cell differentiation
and in response to overexpression of the myogenic basic helix-
loop-helix factor MyoD (18). Here we show that the changes in
GLUT-1 and GLUT-4 expression in rat heart are due, at least
in part, to alterations in the transcriptional rate of both genes.
Moreover, the 299/233 region of the GLUT-1 promoter is also
essential for the transcription of GLUT-1 in rat neonatal car-
diomyocytes in primary culture and that mutation of the Sp1
site at 291/286 region compromises the transcriptional activ-
ity. Furthermore, binding of Sp1 to this site can be detected in
fetal heart and skeletal muscle nuclear extracts but not in
extracts from adult heart and muscle. We also show that this
reduced binding is due to a reduced Sp1 protein abundance in
nuclear extracts from heart and muscle in the adult. Together,
these findings suggest that Sp1 contributes to the high level of
expression of GLUT-1 in the fetal heart.
EXPERIMENTAL PROCEDURES
Materials—[a-32P]dCTP, [a-32P]UTP, and [g-32P]ATP were pur-
chased from ICN, NEN Life Science Products, and Amersham Pharma-
cia Biotech, respectively. Hybond N1 was from Amersham Pharmacia
Biotech, and random primed DNA labeling kit was from Roche Molec-
ular Biochemicals. Immobilon was obtained from Millipore. Most com-
monly used chemicals were from Sigma. Dulbecco’s modified Eagle’s
medium, fetal bovine serum, glutamine, and antibiotics were obtained
from Whittaker (Walkersville, MD). Human recombinant Sp1, a double-
stranded oligonucleotide containing an Sp1 consensus binding site, and
rRNasin were obtained from Promega (Madison, WI).
Clones prGT3 (which contains the 2572-bp1 EcoRI rat GLUT-1 cDNA
insert) and pSM111 (containing the 2470-bp EcoRI rat GLUT-4 cDNA
insert) were kindly provided by Dr. Morris Birnbaum (University of
Pennsylvania, Philadelphia, PA) (19, 20).
Nuclear Run-on—The protocol for the isolation of nuclei was adapted
from one previously described (21), although we introduced several
modifications, described below. Nuclei were isolated from pooled hearts
removed from several litters of anesthetized fetuses or after decapita-
tion of neonates and washed in ice-cold saline. 0.25 g of rat ventricular
muscle was homogenized in 25 ml of NA buffer (1 mM Tris-Cl, pH 8, 300
mM sucrose (Merck), 2.5 mM magnesium acetate, 3 mM dithiothreitol,
0.1 mM phenylmethylsulfonyl fluoride, 0.25% (v/v) Triton X-100, and 40
units of hrRNasin/ml of buffer), with 15 strokes in a motor-driven
Potter-Elvehjem homogenizer in the cold-room. The homogenate was
filtered through four layers of cheesecloth and mixed with one volume
of NB buffer (1 mM Tris-Cl, pH 8, 2.4 M sucrose, 2.5 mM acetate, 3 mM
dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride, 0.1% (v/v) Triton
X-100, and 40 units of rRNasin/ml of buffer). This mixture was layered
onto 12-ml cushions of NB buffer and ultracentrifuged in a SW28
Beckman rotor at 27,000 rpm for 60 min at 4 °C. The supernatant and
the interphase were discarded, and the nuclei pellet was dislodged with
a spatula in 20 ml of NA buffer (without Triton X-100). The nuclear
suspension was centrifuged in a SS34 Sorvall rotor for 10 min at 2000 3
g, and the nuclei resuspended in 1.5 ml of NA buffer (without Triton
X-100). Nuclei were counted in a hemocytometer and pelleted at 4000
rpm for 5 min in a microcentrifuge. The nuclei pellet was resuspended
in Keller storage buffer (22) containing 200 units of rRNasin/ml, frozen
in liquid nitrogen, and stored in 200-ml aliquots of approximately 2 3
107 nuclei each at 280 °C until used.
Nuclear run-on reactions were carried out by incubating approxi-
mately 2 3 107 heart nuclei in a mixture containing 0.625 mM ATP,
0.312 mM CTP, 0.312 mM GTP, 0.625 mM UTP, 0.5 mCi of 800 Ci/mmol
[a-32P]UTP, 300 units of hrRNasin/ml, 40 mM Tris-Cl, pH 8.3, 150 mM
NH4Cl, and 12.5 mM MgCl2, in a final volume of 400 ml, for 20 min at
27 °C. 2-ml samples were removed from the reactions at 0, 5, 10, and 20
min in order to calculate the incorporation of [a-32P]UTP into RNA.
DNA was digested after the addition of an additional 80 units of hrR-
Nasin to each reaction, with 75 ml of RQ1 RNase-free DNase (Promega)
for 20 min at 27 °C, prior to isolation of RNA. This was isolated by
pelleting the nuclei at room temperature for 2 min at low speed. The
supernatant was discarded, and the nuclei were resuspended in 500 ml
of GuSCN solution (4 M guanidinium thiocyanate, 25 mM sodium cit-
rate, 0.5% N-laurylsarcosyne, 0.1 M b-mercaptoethanol). Next, 50 ml of
2 M sodium acetate were added to the nuclei, prior to extracting RNA
with 500 ml of water-equilibrated acid phenol and 100 ml of chloroform:
isoamyl alcohol (49:1) solution. RNA was precipitated with 1 volume of
isopropanol and centrifuged for 5 min at full speed. The RNA pellet was
washed in 70% ethanol and resuspended in GuSCN solution, followed
by another precipitation in 100 ml of isopropanol. The final RNA pellet
was resuspended in 100 ml of TE, pH 8, and 2 ml was counted by liquid
scintillation, in order to calculate the activity of the RNA solution.
Detection of GLUT-4 and GLUT-1 newly transcribed RNA was car-
ried out by hybridization of the labeled RNA to membranes onto which
the plasmids containing the cDNAs for GLUT-1 and GLUT-4 (10 mg of
each per slot) had been previously slot-blotted. Hybridization and
washes were performed as described (21). Data are expressed in ppm as
described previously (23, 24)
GLUT-1 CAT Reporter Constructs, Transient Transfection, and CAT
Assays—Preparation of enriched rat neonatal cardiomyocyte culture
has been described previously (25). Briefly, ventricular myocardium of
1–2-day Sprague-Dawley rat neonates was minced and digested with
collagenase and pancreatin. Isolated cells were collected by centrifuga-
tion, pooled, and then preplated for 30 min on plastic dishes (Primaria,
Becton Dickinson) to remove non-myocytes, which attach rapidly to
plastic. The supernatant, which contains .95% cardiomyocytes as de-
termined by immunohistochemistry with an anti-sarcomeric actin an-
tibody (26)2 was used to seed 0.5 3 106 cells/well in 35-mm gelatin-
coated plastic tissue culture dishes in culture medium (10% horse
serum, 5% fetal bovine serum in 4:1 Dulbecco’s modified Eagle’s medi-
um/199 medium plus 1% (v/v) antibiotics (10,000 units/ml penicillin G
and 10 mg/ml streptomycin), 2 mM glutamine, 25 mM HEPES, pH 7.4)
containing bromodeoxyuridine (100 mM), in order to stop proliferation of
non-myocytic cells.
A series of CAT reporter constructs containing different 59 deletions
of rat GLUT-1 promoter extending to a common 39-end point at 1134
(18) were transfected into cardiomyocytes (10 mg each). Site-directed
mutagenesis of the 299/1134 GLUT-1 CAT construct was performed
with the QuickChange™ kit from Stratagene, according to the manu-
facturer’s instructions. The oligonucleotide used for generating the
mutant construct was 59-CCTCAGGCCCCGTACCCCGGCCCACC-39,
which contains a two-nucleotide substitution (underlined) in the core of
the Sp1 site (see below). The test plasmids were co-transfected with 7.5
mg of b-galactosidase expression plasmid pON239 (27) to normalize for
the efficiency of transfection. Cardiomyocytes were transfected on the
day following isolation by a calcium phosphate protocol (25, 28) and
harvested 2–3 days later for CAT assay (29). For the harvesting of
cardiomyocytes and preparation of cytoplasmic extracts, cells were
washed twice in phosphate-buffered saline and then lysed in 300 ml of
reporter lysis buffer (Promega) according to the manufacturer’s instruc-
tions. After centrifugation in a microcentrifuge for 5 min at 4 °C, the
supernatants were stored at 280 °C.
CAT activity was measured by incubating 75 ml of cytoplasmic ex-
tract with 0.1 mCi of [14C]chloramphenicol, 1.3 mM acetyl-CoA, 200 mM
Tris-HCl, pH 7.5, for 3.5 h at 37 °C. At the end of the incubation,
extraction into ethyl acetate and thin layer chromatography (29) were
performed. The CAT activity was quantitated using an InstantImager
(Packard Instrument Co.). b-Galactosidase activity was measured as
described (30). Data are expressed as percentage of maximum express-
ing construct and represent the average of at least three independent
rounds of transfection.
Electrophoretic Mobility Shift Assays (EMSAs)—Nuclei were isolated
from adult rat ventricular muscle for the preparation of nuclear ex-
tracts essentially as described above (under “Nuclear Run-on”), al-
though a different homogenization procedure was used, given the par-
1 The abbreviations used are: bp, base pair(s); hrSp1, human recom-
binant Sp1; EMSA, electrophoretic mobility shift assay. 2 P. Burton, personal communication.
Role of Sp1 in GLUT-1 Perinatal Repression 17627
ticular features of the tissue. Hearts were removed from 20 male Wistar
rats after cervical dislocation and were washed in ice-cold saline. Atria
were removed from the ventricles, and three sets of ventricular tissue of
4 g each were finely minced with scissors in 35 ml of NA buffer. The
tissue was then homogenized with three strokes of 12 s each at 3000
rpm in a Polytron homogenizer (Kynematica, Littau, Switzerland). The
homogenate was centrifuged at 2600 3 g for 10 min, and the pellets
were resuspended in another 35 ml of fresh NA buffer. The suspension
was further homogenized in a Potter-Elvehjelm homogenizer with eight
strokes of the pestle and then filtered through four layers of cheese-
cloth. The filtered homogenate was centrifuged again at 2600 3 g for 10
min. 25 ml of NA buffer supplemented with Triton X-100 was used in
order to resuspend the pellet, and the suspension was centrifuged again
at 2600 3 g for 10 min. After this last centrifugation, all three pellets
were resuspended in the same 35 ml of NB buffer (see the protocol of the
nuclear run-on), and this volume was ultracentrifuged as described
under “Nuclear Run-on”. The nuclei pellet was saved and processed for
the nuclear extraction.
Nuclei from fetal hind limb skeletal muscle were isolated as de-
scribed under “Nuclear Run-on.” However, 2.2 M sucrose was used for
making NB buffer. As to adult rat skeletal muscle, nuclei were isolated
according to Zahradka et al. (31) and Neufer et al. (32). Nuclei from
L6E9 myoblasts and myotubes were isolated as described (33).
Nuclear extract preparation and EMSAs were performed as de-
scribed previously (18). The 2102/237 probe was obtained by digesting
with AvaII the 2201/1134 CAT construct, purifying the 66-bp frag-
ment, and filling in the cohesive ends with the Klenow fragment of the
DNA polymerase and [a32P]dATP. Both a wild type (wtG1Sp1, 59-
CCTCAGGCCCCGCCCCCCG-39) and a mutated (mutG1Sp1, 59-CCT-
CAGGCCCCGTACCCCG-39; mutation underlined) oligonucleotide en-
compassing positions 2100 to 282 in the rat GLUT-1 proximal
promoter were used as competitors in EMSA. When oligonucleotide
wtG1Sp1 was used as a probe, 20 pmol of double stranded oligonucleo-
tide was end-labeled with [g-32P]ATP by using T4 polynucleotide kinase
(Promega), and 10,000 cpm of the probe was incubated with 5 mg of the
corresponding nuclear extracts as described by Viñals et al. (18). All
competitor oligonucleotides were used at 100-fold molar excess. Super-
shift experiments were performed as described (18).
Electrophoresis and Immunoblotting—SDS-polyacrylamide gel elec-
trophoresis was performed in accordance with the method of Laemmli
(34). Proteins were transferred to Immobilon as reported (35). Transfer
was confirmed by Coomassie Blue staining of the gel after the electro-
blot. An anti-Sp1 affinity-purified rabbit polyclonal antibody (PEP-2,
Santa Cruz Biotechnology) was used at a 5 mg/ml dilution in 1% nonfat
dry milk, 0.02% sodium azide in phosphate-buffered saline and incu-
bated overnight at 4 °C. Detection of the immune complexes with the
rabbit polyclonal antibody was accomplished using the ECL Western
blot detection system (Amersham Pharmacia Biotech). Immunoblots
were performed under conditions in which autoradiographic detection
was in the linear response range.
RESULTS
GLUT-1 and GLUT-4 Transcriptional Activity Is Regulated
during Development—We have previously shown (16) that both
GLUT-4 and GLUT-1 glucose transporters are strongly regu-
lated during perinatal development in heart, skeletal muscle,
and brown adipose tissue. This results in changes to both
mRNA and protein accumulation. The above observations led
us to consider that the induction of GLUT-4 mRNA and repres-
sion of GLUT-1 during perinatal development may be due to
transcriptional control. To test this hypothesis, we carried out
a series of nuclear run-on experiments. These experiments
were performed on nuclei isolated from fetal and neonatal rat
heart, and the transcriptional rate of both GLUT-1 and
GLUT-4 genes was analyzed over a period of time spanning
from fetal day 19 to postnatal day 20. The transcriptional
run-on reactions were linear throughout the experiment (Fig.
1), indicating that the incubation conditions were appropriate
during the reaction, and substrate was not limiting for the
elongation of nascent transcripts. The rate of incorporation of
labeled UTP into RNA inversely correlated with the age of the
animals from which nuclei were prepared. Thus, transcrip-
tional activity was higher in nuclei from fetal heart than in 15-
or 20-day-old neonates. Such a postnatal decrease of general
transcription in rat ventricle agrees with previous observations
(36). Fig. 1B shows an autoradiograph of a run-on reaction
performed with nuclei isolated from 19-day fetal heart. The
signals corresponding to the hybridization of newly transcribed
GLUT-1 and GLUT-4 RNAs were well above that of back-
ground (pBluescript and pGEM), thus indicating that tran-
scription of both genes was active at this developmental stage.
The data corresponding to the transcriptional activity of
GLUT-1 and GLUT-4 genes during rat heart perinatal devel-
opment are shown in Fig. 2. Transcription of GLUT-1 was
maximal in 19-day fetal heart and had decreased by 50% at
birth; in 20-day-old neonates, GLUT-1 transcription was lowest
and accounted for ,25% of the maximal values (Fig. 2). In
contrast, GLUT-4 transcription increased markedly between
the late fetal stage and 20-day-old neonates (a nearly 4-fold
increase). GLUT-4 transcription levels increased very rapidly
after birth, and in 5-day-old neonates were nearly 2-fold
greater than those in fetal heart nuclei. As a control, total RNA
was prepared from hearts saved from the same litters as the
ones used in the nuclear run-on experiments and used to detect
the mRNA levels of GLUT-1 and GLUT-4 glucose transporters
(data not shown). Thus, GLUT-1 mRNA levels in heart were
highest in the fetal stage (18-day-old fetuses) but steadily de-
creased after birth (1- and 20-day-old rats showed 34 and 10%
of the level in 18-day-old fetal heart, respectively), which is in
FIG. 1. The transcriptional activity of nuclei isolated from rat
ventricle decreases with development. Nuclei isolated from pooled
hearts of between 18-day-old fetuses and 15- and 20-day-old neonates
were used in nuclear run-on reactions. Reactions were carried out as
described under “Experimental Procedures,” and the amount of
[32P]UTP incorporated into total RNA was measured during the course
of each reaction. Data are represented as cpm incorporated per nucleus
(A) (F, fetal; N, neonatal). B shows a representative autoradiograph of
a single run-on experiment, corresponding to a reaction in which 2.2 3
107 nuclei isolated from heart of 19-day-old fetuses were used. 2.3 3 106
cpm of total 32P-labeled RNA were added to the hybridization solution.
The slots corresponding to pGEM4Z and pBluescript plasmids are in-
cluded as negative controls and show nonspecific hybridization. This
membrane was exposed to an X-OMAT AR Kodak film for 1 week.
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contrast to the increase in GLUT-4 mRNA abundance observed
over the same period of time (in 17-day-old fetal heart, expres-
sion levels accounted for only 35% of those observed in 20-day-
old rat heart, whereas 5-day-old rat heart contained mRNA
levels similar to those observed in 20-day-old rat heart). Given
the similarity observed between the expression profiles of pro-
tein, mRNA, and transcriptional activity of GLUT-1 and
GLUT-4 transporters in rat ventricle during perinatal devel-
opment, the regulation of these two genes in development ap-
pears to be regulated chiefly at the level of transcription.
The 99-bp Region Upstream of GLUT-1 Transcription Initi-
ation Site Is Sufficient to Drive Transcription in Isolated Car-
diac Myocytes—Our next goal was to identify the cis-elements
that may regulate GLUT-1 transcription and to understand
how GLUT-1 expression was repressed postnatally in heart
and skeletal muscle. In a previous report we showed that the
299/233 fragment in GLUT-1 promoter drives transcriptional
activity of the CAT reporter gene in the L6E9 rat muscle cell
line (18). These findings prompted us to consider that maybe
this region would be also important for the transcription of
GLUT-1 in rat cardiomyocytes. This hypothesis was tested
through the transfection of a series of 59 deletion constructs of
GLUT-1 promoter containing various lengths of the proximal
and 59 upstream sequence through to 1134 fused to the CAT
gene, into primary cultures of rat neonatal cardiomyocytes
prepared from 1–2-day-old neonates (Fig. 3). These experi-
ments showed that transcription was maintained to a high
level in the constructs containing deletions from 2812 to posi-
tion 299 of the GLUT-1 promoter, but deletion of the region
between 299 and 233 relative to GLUT-1 transcription initi-
ation site resulted in an 80% decrease of CAT transcriptional
activity relative to the 299/233 CAT construct. As observed for
the skeletal muscle cell lines, this region, which contains pu-
tative binding sites for known transcription factors, such as
Sp1, AP2, and a CAAT box, (18) appears to be crucial for main-
taining basal transcription in rat neonatal cardiomyocytes.
Sp1 Transcription Factor Is Present in Fetal Heart and Mus-
cle Nuclei Extracts and Binds to a Region Essential for the
Function of the GLUT-1 Promoter—We have reported previ-
ously that Sp1 is able to trans-activate a chimeric construct
containing the rat GLUT-1 promoter inserted upstream of the
CAT reporter gene in L6E9 cells (18), and it binds to a probe
encompassing positions 2102 to 237 of GLUT-1 promoter.
Given the drop in basal transcription of the GLUT-1 promoter
in cardiomyocytes when 59 sequence is deleted from 299 to
233, we used the 2102/237 fragment of GLUT-1 promoter as
a probe to determine whether Sp1 protein was present in
nuclear extracts prepared from fetal or adult rat heart and
skeletal muscle and able to bind to the 291/286 Sp1 binding
site in the GLUT-1 promoter, previously shown to be function-
ally relevant in skeletal muscle cells (18). EMSA experiments
showed that both fetal heart and muscle nuclei extracts gen-
erated a series of protein-DNA complexes when incubated with
the 2102/237 probe (Fig. 4A). Most of these bands are not
present in adult heart and skeletal muscle nuclear extracts.
The arrows in Fig. 4A indicate a band with a slow mobility,
which is specific to fetal heart and skeletal muscle, and also
present in L6E9 myoblast nuclear extracts. This band in the
L6E9 myoblast nuclei extracts was shown in our previous re-
port to be due to the binding of Sp1 factor (18) and disappears
with differentiation of L6E9 myoblasts into myotubes. There-
fore, fetal heart and muscle extracts, but not their adult coun-
FIG. 3. Expression of GLUT-1 promoter 5* deletion constructs
in rat cardiac myocytes. A series of 59 deletions of the upstream
region of the GLUT-1 gene from 2812 to 233 bp relative to the tran-
scription start site were generated as indicated under “Experimental
Procedures.” Rat neonatal cardiomyocytes were transiently transfected
with the indicated constructs and cells were harvested 72 h after trans-
fection. The data are expressed as relative CAT activity/b-galactosidase
activity 6S.E. from three experiments, performed in duplicate, using at
least two preparations of DNA, with the 2812/1134 CAT construct
being set to a value of 100.
FIG. 2. The transcriptional activity of GLUT-1 and GLUT-4 genes is regulated during rat heart perinatal development. Run-on
reactions were performed, as described under “Experimental Procedures,” on nuclei isolated from pooled hearts from animals with ages in a range
between embryonic day 19 to neonatal day 20. Results are expressed in ppm (background value previously subtracted) of the RNA species of
interest relative to newly transcribed total RNA. Data are represented as mean 6 S.E. of 3–8 observations of each sample.
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terparts, may exhibit binding of Sp1 to the GLUT-1 core pro-
moter. To ascertain whether that band in fetal heart and
skeletal muscle extracts corresponds to the Sp1 transcription
factor, we performed competition EMSA experiments by using
a commercial oligonucleotide containing a consensus binding
site for Sp1. This oligonucleotide was able to compete with the
2102/237 probe for the binding of the protein producing the
slow-migrating band, indicating that Sp1 protein may be re-
sponsible for this DNA-protein complex (Fig. 4B). In order to
provide more direct evidence that the Sp1 transcription factor
present in fetal heart and skeletal muscle nuclear extracts
binds to this site in GLUT-1 promoter, we used a polyclonal
antibody against human Sp1 in supershift EMSA (according to
the supplier, this antibody cross-reacts with rat Sp1 and was
therefore appropriate for these studies). When an oligonucleo-
tide encompassing positions 2102 to 282 in GLUT-1 promoter
was radiolabeled and used as a probe, it proved to be able to
bind human recombinant Sp1 protein (hrSp1). This protein was
recognized specifically by the anti-Sp1 antibody, which pro-
duced a decrease in the apparent mobility of the complex
formed by this factor bound to the probe (Fig. 5, left panel). This
supershift was specific, because an irrelevant antibody (IgG)
had no effect on the mobility of the complex (Fig. 5, left panel).
Fetal heart and L6E9 myoblast nuclear extracts were incu-
bated with the same probe and produced several bands (ar-
rows), one of which had the same relative mobility as the one
produced by hrSp1 (Fig. 5, right panel). This band could also be
supershifted by the anti-Sp1 antibody, and this supershift was
observed both in fetal heart and in L6E9 myoblasts and was
specific because the irrelevant antibody was not able to produce
them. These data show that Sp1 is present in fetal heart
nuclear extracts and can bind to the Sp1 site located at 291/
286 in the GLUT-1 promoter. We performed other supershift
experiments with an antiserum against Sp3 (gift of Dr. Gun-
tram Suske, Phillips-Universität, Marburg, Germany) that
showed this other member of the Sp family of transcription
factors was present in the fetal heart nuclear extracts and able
to bind to the same site in GLUT-1 promoter (data not shown).
In order to analyze the functional significance of the 291/
286 Sp1 site in GLUT-1 promoter, we tested the effect that a
point mutation introduced into the 291/286 Sp1 site would
have in (a) the binding of Sp1 to the GLUT-1 promoter, and (b)
the transcriptional activity of the 299/1134 GLUT-1 CAT con-
struct transfected into rat neonatal cardiomyocytes. First, a
mutant version of the oligonucleotide encompassing positions
2102 to 282 in GLUT-1 promoter was used in competition
EMSA experiments. The ability of this oligonucleotide to com-
pete for the binding of Sp1 to the 2102/237 probe was com-
pared with that of the wild type oligonucleotide (Fig. 6A). Thus,
whereas the wild type competitor (wtG1Sp1) was able to com-
pete with the probe, a two-nucleotide substitution in the 291/
286 site (GC3 TA) abolished the ability of the oligonucleotide
FIG. 4. The 2102/237 probe and a Sp1 consensus oligonucleotide compete for the binding of a specific protein present in fetal
heart and muscle nuclear extracts. A, 5 mg of protein nuclear extract from fetal (F) and adult (A) heart or skeletal muscle, as well as from L6E9
myoblast (Mb) and myotube (Mt) nuclear extracts, were incubated as described under “Experimental Procedures” with 10,000 cpm of the
radiolabeled 2102/237 fragment of GLUT-1 promoter. Samples were loaded on a nondenaturing 7% polyacrylamide gel and run at 4 °C and 325
V for 90 min. The gel was then dried and exposed to an AGFA CURIX film. Arrows point to a specific band obtained after incubation with nuclear
extracts from fetal heart, fetal muscle, and L6E9 myoblasts, which was attributed to the binding of Sp1 in L6E9 myoblasts extracts. B, EMSA
experiments were performed by incubating 5 mg of protein from fetal heart or muscle nuclear extracts with 10,000 cpm of the radiolabeled GLUT-1
promoter 2102/237 probe. Arrows point to a specific band obtained after incubation with fetal heart or fetal muscle extracts that was prevented
when the Sp1 consensus oligonucleotide was included as a competitor in some of the reactions (100-fold molar excess).
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to compete in EMSA (Fig. 6A, mutG1Sp1). The same two-
nucleotide substitution was introduced into the core of the Sp1
site in the 299/1134 GLUT-1 CAT construct, and the tran-
scriptional activity of this DNA construct was then compared
with that of the wild type after transfection into rat neonatal
cardiomyocytes. Fig. 6B shows that the mutation induced a
reduction of transcriptional activity of the 299/1134 CAT con-
struct to a value that was 38% of the activity observed in the
wild type. Interestingly, this reduced level of activity is similar
to that of the 233/1134 CAT construct when compared with
the activity of the 299/1134 CAT construct (the activity of the
mutant 299/1134 CAT construct accounts for 75% of the drop
observed when the sequence between 299 and 233 is deleted).
These data indicate the functional significance of this site in
the maintenance of the transcriptional activity of GLUT-1 in
neonatal cardiomyocytes.
Sp1 Levels Are Down-regulated in Adult Cardiac and Skele-
tal Muscle—Additional data were obtained by Western blot
carried out with fetal rat heart, 21-day-old rat heart, and fetal
and adult rat skeletal muscle nuclear extracts. Sp1 protein was
detected in these samples with the same antibody used in the
supershift experiments. This antibody detected a band with an
apparent molecular mass of 106 kDa, which co-migrated with
human recombinant Sp1 (Fig. 7A). Notably, both fetal heart
and muscle extracts contained greater levels of Sp1 protein
than 20-day-old neonatal heart and adult muscle extracts. In
comparison, 21-day-old rat heart extracts only contained 5% of
the levels observed in fetal muscle, and Sp1 protein was barely
detected in the adult skeletal muscle extract under these con-
ditions. These results confirm that Sp1 levels decrease in both
skeletal muscle and heart during perinatal development. In-
deed, strong variations in Sp1 protein expression in nuclear
extracts along with perinatal development have been previ-
ously reported in heart (37), and aortic smooth muscle cells
(38). Moreover, Saffer et al. (39) have reported a wide variation
in Sp1 mRNA levels between tissues in adult mice (in which
they detected extreme differences in Sp1 mRNA levels of up to
100-fold), as well as a decrease in Sp1 mRNA abundance dur-
ing postnatal development in most of the tissues examined. We
also measured Sp3 protein levels in fetal and adult heart nu-
clear extracts with the antiserum against Sp3. Fetal heart
extracts contained high levels of the two reported Sp3 polypep-
tides (40), whereas Sp3 expression was barely detectable in
adult heart extracts, paralleling the pattern of expression ob-
served for Sp1(data not shown).
DISCUSSION
The expression of GLUT-1 and GLUT-4 mRNA levels is
regulated during rat heart perinatal development. Further-
more, GLUT-1 and GLUT-4 mRNA expression in heart corre-
lates with the pattern of protein expression during perinatal
development, which had been reported previously (16). We
show here that these changes in expression represent direct
alterations in the transcriptional activity of GLUT-1 and
GLUT-4 genes, as deduced from nuclear run-on experiments.
We have analyzed the DNA region upstream of the GLUT-1
transcription initiation site in order to look for regions respon-
sible for the control of GLUT-1 transcription in cardiac muscle.
To this end, we have performed transient transfection experi-
ments in rat neonatal cardiomyocytes, with a series of GLUT-1
promoter-CAT chimeric constructs spanning positions 2812 to
233 relative to GLUT-1 transcripition initiation site. These
experiments showed that the 99-bp region upstream of GLUT-1
transcription site are essential for the transcription of GLUT-1
in rat cardiomyocytes. We also showed by electrophoretic mo-
bility shift analysis that the zinc finger transcription factor Sp1
is present in fetal heart and skeletal muscle nuclear extracts
and can bind to a site present in the 2102/237 fragment of
GLUT-1 promoter. This was further demonstrated by super-
shift experiments, using an oligonucleotide encompassing the
Sp1 site located at 291/286 and an antibody raised against rat
Sp1. Furthermore, disruption of the Sp1 site produced a re-
markable decrease in the transcriptional activity of a GLUT-1
promoter-driven CAT construct in neonatal cardiomyocytes,
showing a functionally essential role for Sp1 in the transcrip-
tion of GLUT-1 in those cells. Finally, we have observed that
the levels of expression of Sp1 in nuclear extracts from heart or
muscle in the fetus are higher than those in the adulthood.
Together, these data indicate that the expression of GLUT-1
and GLUT-4 in the developing heart is largely regulated at a
transcriptional level and that Sp1 plays a pivotal role in the
regulation of the expression of GLUT-1 in heart and muscle.
FIG. 5. The Sp1 transcription factor
present in the nuclear extracts from
fetal heart binds to the Sp1 site. Super-
shift experiments were carried out by incu-
bating 5 mg of protein of fetal heart nuclear
extract or L6E9 myoblast (Mb) extract with
10,000 cpm of the radiolabeled oligonucleo-
tide wtG1Sp1 (2102/282 fragment of
GLUT-1 promoter), which contains the pu-
tative Sp1 site present in this region (right
panel). One ml of a commercial solution of
human recombinant Sp1 transcription fac-
tor (hrSp1) was also used in the supershift
experiments as a control (left panel). Sp1
and IgG antibodies stand for a polyclonal
antibody raised against human Sp1 and
MANRX, a polyclonal antibody raised
against rat rBAT amino acid transporter,
respectively. The latter was used as an ir-
relevant antibody in these experiments
(negative control). Arrows point to the
bands specifically displaced by the addition
of the antibody against Sp1.
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Using nuclear run on assays, we were able to observe a
decrease in the transcriptional activity of GLUT-1 during the
perinatal development, which explains the decrease in the
GLUT-1 mRNA and protein levels observed in the same period
(16). The changes in GLUT-1 mRNA expression in rat heart are
probably due to the regulation of the expression of this trans-
porter in cardiomyocytes and not in other cell types, because in
situ hybridization experiments reveal that the expression of
GLUT-1 mRNA in the late fetal heart is higher in the ventric-
ular cardiac muscle than in any of the surrounding tissue.3 We
do not know, however, whether the levels of transcriptional
activity of this gene were higher in earlier stages of rat heart
development prior to embryonic day 17, because isolation of
fetal nuclei from earlier time represented a technically unaf-
fordable task. However, we cannot discard this possibility be-
cause the fetal period is characterized by a high glucose con-
sumption rate, which is typical of cells in an active proliferative
state.
Although both GLUT-1 protein and mRNA are still detecta-
ble in the adult rat heart (16), we found that the postnatal
transcriptional activity of GLUT-1 was very low. These data
suggest potential posttranscriptional regulatory mechanisms.
Such a mechanism has already been postulated for the Na1/
Ca21 exchanger (24) and SR Ca21-ATPase (41). The Na1/Ca21
exchanger in rat heart is also down-regulated perinatally, at
the levels of both protein and mRNA. However, even though
the protein is still detectable in adult rat heart samples, the
transcriptional rate and mRNA expression of this gene fall
below detection levels soon after birth, suggesting a long half-
life for the Na1/Ca21 exchanger protein in the adult rat heart
(24). It is unclear whether the half-life of GLUT-1 is also
developmentally regulated in rat heart. Nevertheless, the sta-
3 P. Thomas, personal communication.
FIG. 7. High abundance of Sp1 transcription factor in fetal
heart and muscle nuclear extracts. Twenty-five mg of protein from
nuclear extracts obtained from fetal heart and muscle, 20-day-old neo-
natal heart, and adult skeletal muscle were loaded together with a 1:5
dilution of hrSp1 (human recombinant Sp1) on a 7.5% acrylamide
minigel, and after electrotransfer onto an Immobilon membrane, Sp1
protein was detected by using PEP2 polyclonal antibody against human
Sp1 factor (see under “Experimental Procedures”). Immunoblots were
autoradiographed and subjected to scanning densitometry in order to
quantify the relative amount of Sp1 in these samples.
FIG. 6. Disruption of the Sp1 binding site in GLUT-1 promoter compromises the binding of Sp1 and the transcription of the
299/1134 GLUT-1 CAT construct in cardiac myocytes. A, 5 mg of protein nuclear extract from fetal heart were incubated as described under
“Experimental Procedures” with 10,000 cpm of the radiolabeled 2102/237 fragment of GLUT-1 promoter. A wild type (wtG1Sp1) and a mutated
version (mutG1Sp1) of an oligonucleotide containing the 291/286 Sp1 site in GLUT-1 promoter were included as competitors (100-fold molar
excess). The arrow points to a band that was competed only by the wtG1Sp1 oligonucleotide and not by the mutant version, in which the consensus
Sp1 site was disrupted. B, either a wild type or a mutated version of 299/1134 GLUT-1 CAT were transiently transfected into rat neonatal
cardiomyocytes as described in Fig. 3 and under “Experimental Procedures.” The sequence at the Sp1 site is shown for both the wild type and the
mutant construct. Note that the same point mutation was included in the mutant competitor oligonucleotide (mutG1Sp1) shown in A. The data
are expressed as relative CAT activity/b-galactosidase activity 6 S.E. from four experiments, with the wild type 299/1134 CAT construct being
set to a value of 100.
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bility of the GLUT-1 mRNA in L6 myoblasts (42), or of the
GLUT-1 protein in 3T3-L1 adipocytes (43), is up-regulated by
oxidative stress and glucose deprivation, respectively. There-
fore, it is likely that posttranscriptional and/or translational
regulatory mechanisms are occurring in addition to the tran-
scriptional regulation we have described.
Heart growth is characterized by a fetal and early neonatal
hyperplastic phase (cell division), which is followed by the
withdrawal of rat cardiomyocytes from the cell cycle (a fact that
is particularly relevant because in adulthood, dead cardiac
myocytes cannot be replaced), and the onset of a hypertrophic
phase of growth (increase in cell mass). Thus, the repression of
GLUT-1 occurs when myocardial cells are still involved in a
period of active replication but are starting to withdraw from
the cell cycle. Although cardiac fibers are fully functional, car-
diomyocytes retain the ability to divide during the hyperplastic
growth phase. This is in contrast to skeletal muscle, where
myoblasts withdraw irreversibly form the cell cycle prior to
differentiation (44). In fact, the incorporation of [3H]thymidine
into DNA in heart is much higher in the late fetal stage than
later on (45), and it decreases rapidly after birth (46, 47),
ceasing completely by the 17th day of neonatal life. From this
moment on, the growth of heart depends exclusively on the
hypertrophy of preexisting cardiomyocytes (48). It is possible
that the signal regulating the perinatal repression of GLUT-1
and induction of GLUT-4 is in some way related to the with-
drawal from the cell cycle. In fact, the expression of GLUT-1 is
rapidly induced by proliferative stimuli, such as growth factors
(49), and is high in transformed cells (50). Moreover, in the
L6E9 muscle cell line, cells exit the cell cycle prior to differen-
tiating into myotubes (44), and this is accompanied by the
parallel repression of GLUT-1 and the induction of GLUT-4
(18).
GLUT-4 transcription is mainly induced postnatally, as de-
duced from our transcriptional activity data. This transporter
is characteristically expressed in differentiated skeletal muscle
and heart. However, the rat heart is already pumping blood as
early as in the ninth day of gestation, and therefore is an organ
with a precocious differentiation. Nevertheless, GLUT-4 tran-
scriptional activation does not occur until the late fetal or early
postnatal phase. This fact indicates that, although the differ-
entiation of cardiac fibers is necessary for the induction of
GLUT-4 expression, this may not be sufficient, and other fac-
tors may be required in order to achieve high GLUT-4 expres-
sion levels. One candidate may be thyroid hormone, because
the responsiveness to this hormone is elicited at the end of the
fetal stage. We have previously shown (17) the pivotal role of
this hormone in the perinatal induction of GLUT-4. A recent
report (51) presents some evidence for the existence of a low-
affinity binding site in the GLUT-4 promoter, in a region that
hadbeenshownasfunctionallyimportantforthethyroidhormone-
dependent regulation of GLUT-4 in the skeletal muscle cell line
C2C12 (52). Nevertheless, we cannot exclude the importance of
other transcription factors, such as those facilitating the estab-
lishment of the differentiated muscle-fiber phenotype, in the
onset of GLUT-4 transcription. In keeping with this, it has
been shown that MEF2A and/or C transcription factors are
able to bind to the human GLUT-4 promoter (53), to a site that
is functionally important for the muscle-specific expression of
this transporter in the C2C12 skeletal muscle cell line (54).
As a first step to characterize the transcription factors reg-
ulating the transcriptional activity of GLUT-1, we looked for
cis-acting regions that may account for the transcriptional ac-
tivity of GLUT-1 in cardiac cells. Our experiments (Fig. 3) show
that the 99 bp upstream of the GLUT-1 transcription initiation
site were essential for basal transcriptional activity in primary
cultures of rat neonatal cardiomyocytes. Next, we tested
whether Sp1 transcription factor, which regulates, to a certain
extent, GLUT-1 transcription in the skeletal muscle cell line
L6E9 (18), might be responsible for the high level of expression
of this glucose transporter in fetal heart. Results from EMSA
experiments indicate that Sp1 binds to a region in the GLUT-1
promoter that we have shown by mutational analysis to be
essential for GLUT-1 transcription in neonatal cardiomyocytes.
Although Sp1 factor was initially considered to have a function
related to the maintenance of the basal transcription of many
genes, an increasing number of studies, including ours, dem-
onstrate that Sp1 regulates the transcription of some genes by
changes in binding activity or expression levels (55, 56), and
also through the interaction with transcription factors, such as
Egr-1 (57), MEF2C (58), and Smad family members (59). In the
case of GLUT-1, Sp1 protein levels in fetal heart and muscle
nuclear extracts, together with its binding activity, correlate
with the high levels of expression observed for GLUT-1 glucose
transporter in the late fetal stage in both tissues. In a recent
report (60), an indispensable role for Sp1 in the development of
the mouse embryo has been shown, given that Sp12/2 homozy-
gous embryos die in utero at about day 11 of gestation. These
embryos show a delayed development although the absence of
Sp1 did not impair the early steps on the formation of heart,
neither of other organs. However, the early death of these
embryos prevents further study about the effects of such a
mutation in the perinatal expression of GLUT-1 in heart.
Our results show that Sp1 expression in heart nuclear ex-
tracts is down-regulated around birth. Little is known about
the regulation of the expression of Sp1. However, in our previ-
ous study (24), we showed that MyoD may be a regulator of Sp1
expression because in cells overexpressing this myogenic fac-
tor, Sp1 levels are dramatically reduced. This suggests the
participation of a myogenic factor in the regulation of the
expression of a gene that may, in turn, be responsible for the
down-regulation of GLUT-1 transcription during terminal dif-
ferentiation of muscle that takes place during perinatal devel-
opment. However, MyoD cannot be exerting this effect on Sp1
during heart development, because neither this myogenic fac-
tor nor its relatives myogenin, myf-5, and MRF4 are expressed
in this organ, but only in developing skeletal muscle. We there-
fore postulate that another unidentified factor might be par-
tially mediating the GLUT-1 repression in cardiac muscle,
through the down-regulation of the levels of expression of Sp1.
Given the parallel between the postnatal reduction of Sp1
levels of expression in heart and the progressive cell cycle
withdrawal experienced by cardiac myocytes along the same
period, it is intriguing to think that cell cycle regulatory pro-
teins may have a role in the perinatal down-regulation of Sp1.
In keeping with this, a tight control of the Sp1-mediated acti-
vation of transcription by Rb and other cell cycle regulatory
proteins has been shown (61–63). However, whether Rb or any
other protein involved in cell cycle control is able to regulate
the expression of Sp1 itself remains unknown. Sp3, another
member of the Sp family of zinc-finger transcription factors,
has been shown to have opposite roles in the regulation of the
transcription of a number of genes. Thus, Sp3 has been attrib-
uted a role as an activator for the transcription of genes such as
SIS/platelet-derived growth factor-B (64), the neuronal nico-
tinic acetylcholine receptor 4 subunit (65), and GLUT-3 (66),
but it has also been well characterized as an inhibitor of Sp1-
mediated transcativation in other genes (40, 67). We have
found that Sp3 is more abundant in extracts from fetal heart
than in adult heart and that the Sp3 transcription factor pres-
ent in fetal extracts is able to bind to the 291/286 Sp1 site in
GLUT-1 promoter. Therefore, Sp3, which is subject to a strong
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regulation during heart development, may have a role in the
regulation of GLUT-1 transcription in heart. In keeping with
this, unpublished data from our laboratory,4 show that, in the
L6E9 myoblasts, Sp3 acts as a negative regulator of GLUT-1
transcription. Moreover, despite both Sp1 and Sp3 being down-
regulated in L6E9 myoblasts along differentiation, alterations
in the relative Sp1/Sp3 ratio at early stages of differentiation
(through a temporary increase in Sp3 abundance) may trigger
the down-regulation of GLUT-1 observed in those conditions.
However, investigating whether a similar mechanism operates
during the down-regulation of GLUT-1 expression in heart
perinatal development and in parallel to the exit of the cardiac
myocytes from the cell cycle lies beyond the scope of the present
study. The identification of the nature of the signals responsi-
ble for the triggering of the perinatal repression of Sp1 and Sp3
in rat heart constitutes an important issue and will be ad-
dressed in future studies.
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